We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05573126
Recruitment Status : Not yet recruiting
First Posted : October 10, 2022
Last Update Posted : October 10, 2022
Information provided by (Responsible Party):
Ellipses Pharma

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : March 2025